Literature DB >> 24419684

Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma.

Michael Weller1, Wolfgang Wick2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24419684     DOI: 10.1038/nrneurol.2013.268

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Authors:  Jeffrey S Wefel; Timothy Cloughesy; James L Zazzali; Maoxia Zheng; Michael Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Asha Das; Henry S Friedman
Journal:  Neuro Oncol       Date:  2011-05-09       Impact factor: 12.300

3.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Authors:  Wolfgang Wick; Christian Hartmann; Corinna Engel; Mandy Stoffels; Jörg Felsberg; Florian Stockhammer; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Richard Meyermann; Marion Rapp; Christof Meisner; Rolf D Kortmann; Torsten Pietsch; Otmar D Wiestler; Ulrike Ernemann; Michael Bamberg; Guido Reifenberger; Andreas von Deimling; Michael Weller
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

5.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

6.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

Review 8.  Molecular neuro-oncology in clinical practice: a new horizon.

Authors:  Michael Weller; Stefan M Pfister; Wolfgang Wick; Monika E Hegi; Guido Reifenberger; Roger Stupp
Journal:  Lancet Oncol       Date:  2013-08       Impact factor: 41.316

9.  Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Authors:  Wolfgang Wick; Christoph Meisner; Bettina Hentschel; Michael Platten; Alissa Schilling; Benedikt Wiestler; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Markus Weiler; Ghazaleh Tabatabai; Andreas von Deimling; Dorothee Gramatzki; Manfred Westphal; Gabriele Schackert; Markus Loeffler; Matthias Simon; Guido Reifenberger; Michael Weller
Journal:  Neurology       Date:  2013-09-25       Impact factor: 9.910

  9 in total
  13 in total

1.  Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Stefano Tomatis; Elena Clerici; Anna Maria Ascolese; Matteo Simonelli; Matteo Perrino; Marco Riva; Marco Rossi; Roberta Rudà; Armando Santoro; Lorenzo Bello; Marta Scorsetti
Journal:  CNS Oncol       Date:  2017-07-18

2.  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Authors:  Benedikt Wiestler; David Capper; Volker Hovestadt; Martin Sill; David T W Jones; Christian Hartmann; Joerg Felsberg; Michael Platten; Wolfgang Feiden; Kathy Keyvani; Stefan M Pfister; Otmar D Wiestler; Richard Meyermann; Guido Reifenberger; Thorsten Pietsch; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-07-15       Impact factor: 12.300

3.  MicroRNA-211 expression is down-regulated and associated with poor prognosis in human glioma.

Authors:  Jun Zhang; Jianguang Lv; Feng Zhang; Hongmin Che; Qiwei Liao; Wobin Huang; Shaopeng Li; Yuqian Li
Journal:  J Neurooncol       Date:  2017-05-27       Impact factor: 4.130

4.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Authors:  Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

5.  Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.

Authors:  Marc C Chamberlain; Donald Born
Journal:  J Neurooncol       Date:  2015-09-04       Impact factor: 4.130

6.  Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis.

Authors:  Xuezhi Dong; Abraham Noorbakhsh; Brian R Hirshman; Tianzan Zhou; Jessica A Tang; David C Chang; Bob S Carter; Clark C Chen
Journal:  Neurooncol Pract       Date:  2015-07-01

Review 7.  Oligodendroglioma: pathology, molecular mechanisms and markers.

Authors:  Pieter Wesseling; Martin van den Bent; Arie Perry
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

8.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

Authors:  Paula Codo; Michael Weller; Gunter Meister; Emese Szabo; Alexander Steinle; Marietta Wolter; Guido Reifenberger; Patrick Roth
Journal:  Oncotarget       Date:  2014-09-15

9.  The future of high-grade glioma: Where we are and where are we going.

Authors:  Emilie Le Rhun; Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2015-02-13

10.  Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.

Authors:  Zhi-Liang Wang; Chuan-Bao Zhang; Jin-Quan Cai; Qing-Bin Li; Zheng Wang; Tao Jiang
Journal:  J Exp Clin Cancer Res       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.